To investigate the clinical application of ultrasound-guided percutaneous lauromacrogol sclerotherapy for symptomatic uterine fibroids.

A total of 63 patients with symptomatic uterine fibroids who were admitted to Hangzhou Cancer Hospital from January 2017 to June 2019 were selected. All patients underwent ultrasound-guided percutaneous lauromacrogol sclerotherapy. Conventional ultrasonography and contrast-enhanced ultrasonography were performed before therapy and 1, 3, 6, and 12 months after therapy. The volume of the tumor was measured. The fibroid shrinkage rate (FSR) and symptom severity score (SSS) were calculated to evaluate the efficacy. Then, the FSR was compared by tumor blood supply, tumor size, and tumor type.

The tumor volume in the 63 cases receiving tumor sclerotherapy showed a continuous shrinking trend. The median FSR at 1, 3, 6, and 12 months after the therapy were 16.98%, 51.69%, 68.07%, and 80.83%, respectively. The median SSSs at 3, 6, and 12 months after therapy (21.88, 12.50, and 9.38, respectively) were significantly lower than that before therapy (28.13; Z=-6.990, -9.035, and -9.464, P＜0.001 for all). FSR was lowest in the grade Ⅲ blood supply subgroup,＞5 cm myoma subgroup, and subplasma myoma subgroup, with a median FSR of 78.16%, 66.35%, and 76.97%, respectively. There were 19 (30.1%, 19/63) cases with adverse reactions that did not require treatment during and after the therapy, and no other serious complications occurred.

Ultrasound-guided percutaneous lauromacrogol sclerotherapy for symptomatic uterine fibroids is minimally invasive and effective, and has fewer complications, but it is less effective for fibroids＞5 cm, those with rich blood supply, and subplasma fibroids.